Skip to main content

Advertisement

SpringerLink
Log in

Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX

  • Letter to the editor
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825

    Article  PubMed  CAS  Google Scholar 

  2. Gralla RJ, de Wit R, Herrstedt J et al (2005) Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 104:864–868

    Article  PubMed  CAS  Google Scholar 

  3. Poli-Bigelli S, Rodrigues-Pereira J et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090–3098

    Article  PubMed  CAS  Google Scholar 

  4. Merck & Co., Inc. (2011) Prescribing information. EMEND (aprepitant) capsules. www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf. Accessed 20 Aug 2013

  5. Nieva JJ, Webb W, Siuzdak G (2007) Pharmacokinetic effect of aprepitant on irinotecan in patients with colorectal cancer. In: ASCO annual meeting proceedings, abstract no. 19622. J Clin Oncol 25(18S)

Download references

Conflict of interest

There are no financial disclosures or conflicts of interest for any of the authors. We have full control of all primary data, and we agree to allow the journal to review our data.

Author information

Authors and Affiliations

  1. Medical Oncology Unit, National Cancer Institute “Giovanni Paolo II”, Viale Orazio Flacco, 65, 70124, Bari, Italy

    Nicola Silvestris

  2. Scientific Direction, National Cancer Institute “Giovanni Paolo II”, Bari, Italy

    Anna Elisabetta Brunetti

  3. Medical Oncology Unit, University Campus Biomedico, Rome, Italy

    Marco Russano

  4. Pharmacy Department, National Cancer Institute “Giovanni Paolo II”, Bari, Italy

    Patrizia Nardulli

Authors
  1. Nicola Silvestris
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Elisabetta Brunetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Russano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrizia Nardulli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Silvestris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Silvestris, N., Brunetti, A.E., Russano, M. et al. Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Support Care Cancer 21, 2955–2956 (2013). https://doi.org/10.1007/s00520-013-1944-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-1944-y

Keywords

Search

Navigation